28,826 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Seven Fleet Capital Management LP

Key Points

• Seven Fleet Capital Management initiated a position of 28,826 Axsome Therapeutics shares, representing about 0.06% of the company and 1.2% of the firm’s portfolio. Institutional investors collectively own 81.49% of AXSM.
• Axsome’s latest quarter fell short of expectations, with an EPS loss of $0.99 versus the $0.89 consensus and revenue of $218.38 million versus estimates of $221.11 million. Analysts expect a full-year loss of approximately $2.80 per share.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $267.60, although HC Wainwright reduced its 2026 and 2027 earnings forecasts. Shares recently opened at $207.15, below the consensus target.

Seven Fleet Capital Management LP bought a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 28,826 shares of the company's stock, valued at approximately $7,055,740,000. Axsome Therapeutics makes up about 1.2% of Seven Fleet Capital Management LP's portfolio, making the stock its 20th largest holding. Seven Fleet Capital Management LP owned approximately 0.06% of Axsome Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Pictet Asset Management Holding SA lifted its stake in Axsome Therapeutics by 20.4% during the 4th quarter. Pictet Asset Management Holding SA now owns 436,063 shares of the company's stock worth $79,643,000 after acquiring an additional 73,925 shares in the last quarter. Norges Bank acquired a new stake in shares of Axsome Therapeutics in the 4th quarter valued at $90,490,000. Axiom Investors LLC DE lifted its stake in Axsome Therapeutics by 28.7% during the fourth quarter. Axiom Investors LLC DE now owns 63,390 shares of the company's stock worth $11,578,000 after purchasing an additional 14,137 shares during the last quarter. Legato Capital Management LLC lifted its position in Axsome Therapeutics by 90.6% in the fourth quarter. Legato Capital Management LLC now owns 9,627 shares of the company's stock valued at $1,758,000 after acquiring an additional 4,576 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in shares of Axsome Therapeutics by 60.1% during the fourth quarter. BNP Paribas Financial Markets now owns 304,388 shares of the company's stock worth $55,593,000 after acquiring an additional 114,282 shares during the last quarter. Hedge funds and other institutional investors own 81.49% of the company's stock.

Key Headlines Impacting Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating on Axsome Therapeutics, signaling continued confidence in the company’s long-term commercial outlook despite lowering its earnings forecasts.
• Neutral Sentiment: The firm continues to project a significant improvement in profitability in 2027, with positive earnings expected beginning in the second quarter and full-year 2027 EPS forecast at $5.25.
• Neutral Sentiment: A report showing zero short interest as of August 25 does not indicate meaningful short-selling pressure, although the data appears inconsistent because it also reports no change from the prior period.
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS estimate to a loss of $4.10 from a loss of $3.89, while cutting forecasts for third-quarter and fourth-quarter 2026 EPS to losses of $0.95 and $0.91, respectively.
• Negative Sentiment: The analyst also lowered its 2027 estimates: first-quarter EPS was revised to a $0.27 loss from $0.05 in earnings, second-quarter EPS to $1.06 from $1.30, third-quarter EPS to $1.92 from $2.30, and full-year EPS to $5.25 from $6.47. Fourth-quarter 2027 EPS was reduced to $2.53 from $2.81.

Axsome Therapeutics Stock Performance

Shares of AXSM opened at $207.15 on Thursday. The firm's 50 day moving average is $229.34 and its 200-day moving average is $206.61. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.43 and a quick ratio of 1.34. The stock has a market capitalization of $10.85 billion, a P/E ratio of -55.24 and a beta of 0.65. Axsome Therapeutics, Inc. has a 12-month low of $112.90 and a 12-month high of $260.19.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.10). Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. The firm had revenue of $218.38 million for the quarter, compared to analyst estimates of $221.11 million. Equities research analysts anticipate that Axsome Therapeutics, Inc. will post -2.8 EPS for the current fiscal year.

Insider Buying and Selling at Axsome Therapeutics

In related news, CEO Herriot Tabuteau sold 4,660 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $213.95, for a total transaction of $997,007.00. Following the completion of the sale, the chief executive officer directly owned 7,229 shares of the company's stock, valued at approximately $1,546,644.55. This represents a 39.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Susan Mahony sold 300 shares of the company's stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $237.21, for a total value of $71,163.00. Following the sale, the director owned 1,129 shares in the company, valued at approximately $267,810.09. This represents a 20.99% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 200,766 shares of company stock worth $46,685,646 over the last 90 days. Company insiders own 20.60% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on AXSM shares. Jefferies Financial Group reissued a "buy" rating and set a $380.00 price target on shares of Axsome Therapeutics in a report on Thursday, June 11th. Deutsche Bank Aktiengesellschaft set a $280.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday, May 5th. UBS Group reissued a "buy" rating on shares of Axsome Therapeutics in a research report on Monday. Needham & Company LLC upped their price target on Axsome Therapeutics from $267.00 to $268.00 and gave the stock a "buy" rating in a research note on Tuesday, August 11th. Finally, Truist Financial upgraded shares of Axsome Therapeutics to a "strong-buy" rating in a report on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $267.60.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome's pipeline includes several late-stage and approved product candidates.

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source